Tag Archive for: Roche

HOOKIPA has received a US$10m milestone under its 2022 agreement with Roche to develop an arenaviral immunotherapy for KRAS-mutated cancers.

Roche AG’s US subsidiary Genentech Inc has withdrawn its checkpoint inhibitor atezolizumab from the market after disappointing results in bladder cancer.

Schwan follows Franz, Schinecker follows Schwan.